The promise and pitfalls of long-acting injectable agents for HIV prevention

Current Opinion in HIV and AIDS

Volumn 11, Issue 1, 2016, Pages 122-128

  Landovitz, Raphael J ^a   Kofron, Ryan ^a   McCauley, Marybeth ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b FAMILY HEALTH INTERNATIONAL   (United States)

Author keywords

cabotegravir; HIV 1; long acting injectable antiretroviral; preexposure prophylaxis; rilpivirine

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CABOTEGRAVIR; CORTICOTROPIN; HYDROCORTISONE; RILPIVIRINE; DELAYED RELEASE FORMULATION;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; CORTICOTROPIN BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHILIA; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROCORTISONE BLOOD LEVEL; INJECTION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INSOMNIA; MEDICATION COMPLIANCE; NAUSEA; NEPHROTIC SYNDROME; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRE-EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SKIN MANIFESTATION; ADMINISTRATION AND DOSAGE; ADVERSE EFFECTS; CHEMOPROPHYLAXIS; DELAYED RELEASE FORMULATION; DISEASE TRANSMISSION; HIV INFECTIONS; PREVENTION AND CONTROL; PROCEDURES; TRANSMISSION; UNITED STATES;

ANTI-HIV AGENTS; CHEMOPREVENTION; CLINICAL TRIALS, PHASE II AS TOPIC; DELAYED-ACTION PREPARATIONS; DISEASE TRANSMISSION, INFECTIOUS; HIV INFECTIONS; HUMANS; INJECTIONS; PRE-EXPOSURE PROPHYLAXIS; RILPIVIRINE; UNITED STATES;

EID: 84950249101     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000219     Document Type: Review

References (28)

1. Grant R, Lama J, Anderson P, et al. Preexposure chemoprophylaxis for HIV preventioninmenwhohavesex withmen. NEngl JMed2010;363:2587-2599.
2. Grant R, Anderson P, McMahan V, et al. Uptake of preexposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet 2014; 14:820-829.
3. Molina J, Capitant C, Spire B, et al. On demand PrEP with oral TDF-FTC in MSM: Results of the ANSR Ipergay trial [Abstract 23LB]. 22nd Conference on Retroviruses and Opportunistic Infections (CROI); 23-26 February 2015; Seattle, Washington.
4. McCormack S, Dunn D, Desai, M. et al. Pragmatic open-label randomised trial of preexposure prophylaxis: The PROUD study Lancet online 2015 dx. doi.
5. Baeten J, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399-410.
6. Hendrix C. Exploring concentration response in HIV preexposure prophylaxis to optimize clinical care and trial design. Cell 2013; 155:515-518.
7. AIDS Vaccine Advocacy Coalition (AVAC). Preexposure prophylaxis (PrEP) by the numbers: efficacy, regulatory approval and more; 2015. http://www.avac. org/sites/default/files/resource-files/By-The-Numbers-PrEP. pdf. [Accessed 17 August 2015]
8. Anderson P, Glidden D, Liu A, et al. Emtricitabine-tenofovir concentrations and preexposure prophylaxis efficacy in men who have sex with men. Sci Transl Med 2012; 4:151ra125.
9. Cottrell M, Yang K, Prince H, et al. Predicting effective truvada PrEP dosing strategies with a novel PK-PD model incorporating tissue active metabolites and endogenous nucleotides (EN) [Abstract OA22. 06 LB]. HIV Research for Prevention (HIV R4P); 28-31 October 2014; Cape Town, South Africa.
10. Patterson K, Prince H, Kraft E, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med 2011; 3:112re114.
11. Gunawardana M, Remedios-ChanM, Miller C, et al. Pharmacokinetics of longacting tenofoviralafenamide (GS-7340) subdermal implant for HIV prophylaxis. Antimicrob Agents Chemother 2015; AAC-00656.
12. Andrews C, Spreen W,Mohri H, et al. Long-Acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. Science 2014; 343:1151-1154.
13. Spreen W, Lowry A, Pal R, et al. Correlation of in vivo cabotegravir concentration and prevention of SIV in macaques [Abstract 966LB]. 22nd Conference on Retroviruses and Opportunistic Infections (CROI); 23-26 February 2015; Seattle, Washington.
14. Margolis D, Brinson C, Eron J, et al. 744 and rilpivirine as two-drug oral maintenance therapy: Lai116482 (latte) week 48 results [Abstract 91LB]. 21st Conference on Retroviruses and Opportunistic Infections (CROI); 3-6 March 2014; Boston, Massachusetts.
15. Margolis D, Brinson C, Smith G, et al. Cabotegravir and rilpivirine as 2-drug oral maintenance therapy: LATTE W96 results [Abstract 554LB]. 22nd Conference on Retroviruses and Opportunistic Infections (CROI); 23-26 February 2015; Seattle, Washington.
16. Azijn H, Tirry I, Vingerhoets J, et al. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTIresistant HIV-1. Antimicrob Agent Chemother 2010; 54:718-727.
17. Garvey L, Winston A. Rilpivirine: A novel nonnucleoside reverse transcriptase inhibitor. Expert Opin Investig Drugs 2009; 18:1035-1041.
18. Snyder O, Vincent H, Lachau-Durant S, et al. Preclinical evaluation of TMC-278LA, a long-Acting formulation of rilpivirine, demonstrates significant protection from vaginal HIV infection [Abstract OA03. 01]. HIV Research for Prevention (HIV R4P); 28-31 October 2014; Cape Town, South Africa.
19. Jackson A, Else L, Mesquita P, et al. A compartmental pharmacokinetic evaluation of long-Acting rilpivirine in HIV-negative volunteers for preexposure prophylaxis. Clin Pharmacol Ther 2014; 96:314-323.
20. McGowan I, Siegel A, Duffill K, et al. A phase 1 open label safety, acceptability, pharmacokinetic, and pharmacodynamic study of intramuscular TMC278LA (the MWRI-01 study) [Abstract OA27. 06 LB]. HIV Research for Prevention (HIV R4P); 28-31 October 2014; Cape Town, South Africa.
21. Penrose K, Parikh U, Hamanishi K, et al. Selection of rilpivirine resistant HIV-1 in a seroconverter on long-Acting rilpivirine (TMC278LA) from the lowest dose arm of the SSAT 040 trial [Abstract OA27. 01]. HIV Research for Prevention (HIV R4P); 28-31 October 2014; Cape Town, South Africa.
22. Murphy P, Brixner D. Hormonal contraceptive discontinuation patterns according to formulation: investigation of associations in an administrative claims database. Contraception 2008; 77:257-263.
23. Leite IC, Gupta N. Assessing regional differences in contraceptive discontinuation, failure and switching in Brazil. Reprod Health 2007; 4:6.
24. Margolis DA, Brinson CC, Smith GHR, et al. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. Lancet 2015; 15:1145-1155.
25. Lou Y, Gould E, Chen S, et al. Meta-Analysis of safety data from 8 clinical studies with GSK1265744, an HIV integrase inhibitor, dosed orally or as injection of long-Acting parenteral nanosuspension (LAP) [Abstract 1752]. 53rd ICAAC Interscience Conference on Antimicrobial Agents and Chemotherapy; 10-13 September 2013; Denver, Colorado.
26. Spreen W, Min S, Ford S, et al. Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor. HIV Clin Trials 2013; 14:192-203.
27. Wilkin A, Poznaik AL, Morales-Ramirez J, et al. Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviralnaive patients: Week 192 results from a phase IIb randomized trial. AIDS Res Hum Retroviruses 2012; 28:437-446.
28. Sugarman J. Ethical considerations regarding oral preexposure prophylaxis in HIV prevention trials. Curr Opin HIV AIDS 2016; 11:109-115.